Overview

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Treatments:
Control Groups